Sponsor: SWOG
Sponsor Study ID: S2302
Study Title: A Prospective Randomized Study of Ramucirumab (LY3009806;NSC749128) Plus Pembrolizumab (MK-3475;NSC776864) Versus Standard of Care for Participants Previously Treated with Immunotherapy for Stage IV or Recurrent non-Small Cell Lung Cancer
CTO #: 103908
NCT Number: NCT05633602
Phase: III
Protocol Type: Treatment
Age Group: Adults
Disease Sites: Lung
Study Objectives: To compare overall survival (OS) in participants previously treated with platinum-based chemotherapy and immunotherapy for Stage IV or recurrent non-small cell lung cancer (NSCLC) randomized to pembrolizumab and ramucirumab versus standard of care. To summarize reports of serious and unexpected high-grade (≥ Grade 3) treatment-related adverse events determined by the treating physician within each treatment arm.